Al­ler­gan’s deal spree con­tin­ues with $2.9B Life­Cell buy­out

Al­ler­gan isn’t let­ting the hol­i­days get in the way of its deal spree. The com­pa­ny has snapped up Life­Cell and its aes­thet­ic and re­gen­er­a­tive medtech for $2.9 bil­lion in cash.

The deal gives Al­ler­gan a port­fo­lio that in­cludes:

• Acel­lu­lar Der­mal Ma­tri­ces, com­mon­ly used in breast re­con­struc­tion pro­ce­dures and com­plex her­nia surg­eries to pro­vide soft tis­sue sup­port;
• Al­lo­derm, a hu­man al­lo­graft tis­sue ma­trix which “al­lows for a strong, in­tact re­pair in chal­leng­ing pro­ce­dures and is in­tend­ed to be used for re­pair or re­place­ment of dam­aged or in­ad­e­quate soft tis­sue, in­clud­ing breast re­con­struc­tion post-mas­tec­to­my;”
• Re­volve, a sin­gle use high-vol­ume fat graft­ing de­vice that us­es pa­tients’ own fat to en­hance vol­ume in plas­tic and re­con­struc­tive pro­ce­dures.

The buy­out al­so in­cludes Life­Cell’s R&D op­er­a­tions in New Jer­sey.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER